Injection drug use and patterns of highly active antiretroviral therapy use: An analysis of ALIVE, WIHS, and MACS cohorts

被引：22

作者：

Morris J.D. ^{[1
]}

Golub E.T. ^{[1
]}

Mehta S.H. ^{[1
]}

Jacobson L.P. ^{[1
]}

Gange S.J. ^{[1
]}

机构：

[1] Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD

来源：

AIDS Research and Therapy | / 4卷 / 1期

关键词：

Human Immunodeficiency Virus; Injection Drug; Multicenter AIDS Cohort Study; Adjusted Relative Hazard; Multicenter AIDS Cohort Study Participant;

D O I：

10.1186/1742-6405-4-12

中图分类号：

学科分类号：

摘要：

Background: Sustained use of antiretroviral therapy has been consistently shown to be one of the primary predictors of long-term effectiveness. Switching and discontinuation reflect patient and provider decisions that may limit future treatment options. In this study, we utilize data reported at semi-annual study visits from three prospective cohort studies, the AIDS Link to IntraVenous Exposure (ALIVE), the Women's Interagency HIV Study (WIHS), and the Multicenter AIDS Cohort Study (MACS), to investigate determinants of HAART modification with a particular focus on reported injection drug use (IDU). Methods: Longitudinal data collected between 1996 and 2004 contributed from 2,266 participants (37% with a reported history of IDU) who reported initiating their first HAART regimen during follow-up were utilized. Separate proportional-hazards models were used to identify factors measured prior to HAART-initiation associated with the time to first HAART discontinuation and first switch of components of HAART among continuous HAART users. Results: The use of PI- vs. NNRTI-based regimens among HAART users with and without any history of IDU was similar over follow-up. The median time to a first report of discontinuation of HAART was 1.1 years for individuals with a history of IDU but 2.5 years for those without a history of IDU and multivariate analyses confirmed overall that individuals with a history of IDU were at greater risk for HAART discontinuation (adj RH = 1.24, 95% CI: 1.03-1.48). However, when restricting to data contributed after 1999, there was no longer any significant increased risk (adj RH = 1.05, 95% CI: 0.81-1.36). After adjusting for pre-HAART health status and prior ARV exposure, individuals who were ethnic/racial minorities, reported an annual income < $10,000/year, and were not employed were at significantly greater risk for HAART discontinuation. The median time to a first change in HAART regimen was approximately 1.5 years after first HAART report and was not elevated among those with a history of IDU (adj RH = 1.09, 95% CI: 0.89-1.34). Conclusion: Our analyses demonstrate that injection drug use by itself does not appear to be an independent risk factor for HAART switching or discontinuation in more recent years. However, as continued HAART use is of paramount importance for long-term control of HIV infection, efforts to improve maintenance to therapy among disadvantaged and minority populations remain greatly needed. © 2007 Morris et al; licensee BioMed Central Ltd.

引用

共 28 条

[1]

Palella Jr. F.J., Delaney K.M., Moorman A.C., Loveless M.O., Fuhrer J., Satten G.A., Aschman D.J., Holmberg S.D., Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection, N Engl J Med, 338, pp. 853-860, (1998)

[2]

Gange S.J., Barron Y., Greenblatt R.M., Anastos K., Minkoff H., Young M., Kovacs A., Cohen M., Meyer III W.A., Munoz A., Effectiveness of highly active antiretroviral therapy among HIV-1 infected women, J Epidemiol Community Health, 56, pp. 153-159, (2002)

[3]

Friedland G.H., HIV medication adherence. The intersection of biomedical, behavioral, and social science research and clinical practice, J Acquir Immune Defic Syndr, SUPPL. 1, pp. 3-9, (2006)

[4]

Chesney M.A., The elusive gold standard. Future perspectivesfor HIV adherence assessment and intervention, J Acquir Immune Defic Syndr, SUPPL. 1, pp. 149-155, (2006)

[5]

Mehta S., Moore R.D., Graham N.M.H., Potential factors affecting adherence with HIV therapy, AIDS, 11, pp. 1665-1670, (1997)

[6]

Libman H., Makadon H.J., Antiretroviral Therapy, HIV, (2003)

[7]

Deeks S.G., Wrin T., Liegler T., Hoh R., Hayden M., Barbour J.D., Hellmann N.S., Petropoulos C.J., McCune J.M., Hellerstein M.K., Grant R.M., Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia, N Engl J Med, 344, pp. 520-522, (2001)

[8]

Ahdieh Grant L., Silverberg M.J., Palacio H., Minkoff H., Anastos K., Young M.A., Nowicki M., Kovacs A., Cohen M., Munoz A., Discontinuation of potent antiretroviral therapy: Predictive value of and impact on CD4 cell counts and HIV RNA levels, AIDS, 15, pp. 2102-2108, (2001)

[9]

Barron Y., Cole S.R., Greenblatt R.M., Cohen M.H., Anastos K., DeHovitz J.A., Delapenha R., Gange S.J., Effect of discontinuing antiretroviral therapy on survival of women initiated on highly active antiretroviral therapy, AIDS, 18, pp. 1579-1584, (2004)

[10]

Van Roon E.N., Verzijl J.M., Juttmann J.R., Lenderink A.W., Blans M.J., Egberts A.C.G., Incidence of discontinuation of highly active antiretroviral combination therapy (HAART) and its determinants, J Acquir Immun Defic Human Retrovir, 20, pp. 290-294, (1999)

← 1 2 3 →